Abstract. TRIP-Br1 oncoprotein is known to be involved in many vital cellular functions. In this study, we examined the role of TRIP-Br1 in hypoxia-induced cell death. Exposure to the overcrowded and CoCl 2 -induced hypoxic conditions increased TRIP-Br1 expression at the protein level in six breast cancer cell lines (MCF7, MDA-MB-231, T47D, Hs578D, BT549, and MDA-MB-435) but resulted in no significant change in three normal cell lines (MCF10A, MEF and NIH3T3). Our result revealed that CoCl 2 -induced hypoxia stimulated apoptosis and autophagy, in which TRIPBr1 expression was found to be upregulated. Interestingly, TRIP-Br1 silencing in the MCF7 and MDA-MB-231 cancer cells accelerated apoptosis and destabilization of XIAP under the CoCl 2 -induced hypoxic condition, implying that TRIP-Br1 may render cancer cells resistant to apoptosis through the stabilization of XIAP. We also propose that TRIP-Br1 seems to be upregulated at least partly as a result of the inhibition of PI3K/AKT signaling pathway and the overexpression of HIF-1α. In conclusion, our findings suggest that TRIP-Br1 functions as an oncogenic protein by providing cancer cells resistance to the hypoxia-induced cell death.
Introduction
The environment surrounding cells or tissues is considered to be an important factor affecting their biological progress, including cell growth, proliferation, tumorigenesis, and cell death. During tumorigenesis, cancer cells are under extremely stressful conditions (e.g., nutrient starvation, acidic, or hypoxic conditions) because of their uncontrolled growth and proliferation (1) (2) (3) . Hypoxia, a condition of a poor oxygen supply, plays a vital role in tumorigenesis, angiogenesis, metabolism, proliferation, metastasis, and cell death (4) (5) (6) (7) (8) (9) . When cells are initially exposed to hypoxia, they stimulate particular adaptive responses such as autophagy, which regulate a series of physiological and cellular mechanisms necessary for survival (10) (11) (12) (13) (14) (15) . Further severe hypoxia eventually results in apoptotic cell death (14, (16) (17) (18) . Although cancer cells are usually much more sensitive than normal cells to such stress, they seem to have developed adaptive mechanisms at different molecular levels to withstand this extreme environmental condition and to delay or suppress cell death, thus aggravating tumorigenesis (19) (20) (21) . Therefore, the precise understanding of the molecular mechanism of hypoxia-induced cancer cell growth and death appears to be very important in cancer research and treatment.
In an effort to identify the proteins responsible for the resistance of cancer cells to hypoxia-induced cell death, we initially focused on TRIP-Br1, the transcriptional regulator interacting with PHD-bromodomain 1 (also known as SERTAD1, p34SEI-1 or SEI-1), a member of the TRIP-Br family. TRIP-Br1 is known to be involved in various important biological functions, such as transcription, cell cycle progression, metabolism, metastasis, tumorigenesis, and cell death (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . However, little is known about its cellular function under hypoxic condition. It is now widely accepted that many oncoproteins suppress autophagy and apoptosis, whereas tumor suppressors mostly induce them (32, 33) . In our previous study, we showed that the expression of TRIP-Br1 oncoprotein significantly increased in response to nutrient starvation, rending cancer cells resistant to cell death by suppressing three types of representative programed cell deaths (type I apoptosis, type II autophagy-induced cell death, and type III/IV necrosis/necroptosis) (34) . Therefore, it was hypothesize that TRIP-Br1 might inhibit cell death under hypoxic condition.
In this study, we attempted to clarify how TRIP-Br1 contributes to the survival of cancer cells under hypoxic condition during tumor growth.
Materials and methods
Cell lines, cell cultures, and materials. Six breast cancer cell lines (MCF7, MDA-MB-231, T47D, Hs578D, BT549, and MDA-MB-435) and two fibroblast normal cell lines (MEF and NIH3T3) were cultured in Dulbecco's modified Eagle's medium (DMEM; Welgene Inc., Daegu, Korea) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Carlsbad, CA, USA) and 1% antibiotic-antimycotic (Gibco BRL). MCF10A normal breast epithelial cells were grown in DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA, cat. 11330-032) supplemented with 20 ng/ml of epithelial growth factor (EGF; Sigma-Aldrich, cat. E9644), 100 ng/ml of cholera toxin (Sigma-Aldrich, cat. C-8052), 10 µg/ml of insulin (Sigma-Aldrich, cat. I-9278), 0.5 mg/ml of hydrocortisone (Sigma-Aldrich, cat. H-0888), 5% horse serum (Invitrogen, cat. 16050-122), and 1% antibioticantimycotic. All cells were cultured at 37˚C in a humidified atmosphere composed of 5% CO 2 . Cell lines were purchased from the American Type Culture Collection (ATCC). Cobalt chloride (CoCl 2 ) and LY294004 were purchased from SigmaAldrich (cat. STBC9672V) and Calbiochem, San Diego, CA, USA (cat. 440202), respectively.
Western blot analysis.
Immunoblotting analysis was performed as previously described (35 
Reverse transcription polymerase chain reaction (RT-PCR)
analysis. Total RNA was extracted from MCF7, MDA-MB-231, and MCF10A cells by using an RNeasy mini kit (Qiagen, Hilden, Germany). For reverse transcription, 1 µg of RNA from each sample was subjected to cDNA synthesis using the TOPscript™ RT 2X PreMIX kit (Enzynomics, cat. RT203-50-F, Korea) according to the manufacturer's instructions. Each gene product was amplified using 10 ng of cDNA, the corresponding pair of primers, and an AccuPower PCR PreMix system (Bioneer, cat. K-2016, Korea), in which the β-actin gene product was used as an internal control. The oligonucleotide sequences for RT-PCR analysis were pRT-HIF-1α-F/R: Analysis of apoptosis and autophagy. Apoptosis and autophagy were mainly analyzed by employing western blotting with corresponding markers or regulatory proteins: PARP, Bax, and XIAP for apoptosis; SQSTM1/p62 and LC3 for autophagy. Cell viability was evaluated by means of the MTT assay following our previous method (36) .
Results
Upregulated TRIP-Br1 expression in overcrowded and hypoxic conditions. During tumorigenesis, the uncontrolled growth of cancer cells gives rise to oxygen deficiency and nutrient starvation and eventually cancer cells are under much more stressful condition compared to normal cells. To elucidate how cancer cells overcome these stressful environments and continue growing, we cultured six breast cancer cell lines (MCF7, MDA-MB-231, T47D, Hs578D, BT549, and MDA-MB-435) and normal cell lines (MCF10A, MEF, and NIH3T3) in complete media until cell densities reached ~80% confluence to serve as the normal control (NC) or until the cells reached a very high cell density and became overcrowded (OC). Our previous data revealed that overcrowded condition increased TRIP-Br1, but decreased TRIP-Br3 at the protein level (34, 37) . We proposed that a balance between TRIP-Br1 and TRIP-Br3 levels seems to be crucial to cell survival and death (34, 37) .
TRIP-Br3 (also known as SEI-3/CDCA4/Hepp) is a putative tumor suppressor whereas TRIP-Br1 is an onco protein even though both of them belong to the same TRIP-Br family (35, (38) (39) (40) . Therefore, the levels of TRIP-Br1 and TRIP-Br3 expression were determined under condition of overcrowding. Noteworthy, TRIP-Br1 expression increased significantly in all six cancer cell lines but only slightly in the three normal cell lines, which were not overcrowded, probably because their growth and proliferation were controlled (i.e., in a monolayer with ~90% confluence) (Fig. 1A) . In contrast, TRIP-Br3 expression decreased in both the cancer cells and the normal cells, in which TRIP-Br3 expression decreased to a greater extent in the normal cells than the cancer cells (Fig. 1A) . In an effort to find what kind of stressful condition(s) is responsible for the TRIP-Br1 upregulation and TRIP-Br3 downregulation under the overcrowded condition, we previously showed that decreased nutrients (such as serum, glucose, and amino acids) affect TRIP-Br1 and TRIP-Br3 expression (34, 37 ). An overcrowded environment leads to another type of extreme stress than that caused by hypoxia, as well as nutrient starvation. Our data showed that HIF-1α expression, a marker of hypoxia, increased as a result of overcrowding, suggesting the presence of hypoxia in an overcrowded environment (Fig. 1A) .
Assuming that TRIP-Br1 and TRIP-Br3 expression might be affected at least in part by overcrowding-induced hypoxia, we examined their expression levels under cobalt chloride (CoCl 2 )-mediated hypoxic condition. The same cell lines were treated with 0.8 mM of CoCl 2 , a well-established chemical inducer of hypoxia-like responses (4). TRIP-Br1 expression was significantly increased in all six cancer cell lines, but no significant change was detected in the three normal cell lines when they were exposed to CoCl 2 -generated hypoxia (Fig. 1B) . In contrast, TRIP-Br3 expression decreased in both cancer cells and normal cells (Fig. 1B) . These results suggest that the hypoxic condition is responsible for TRIP-Br1 up regulation and TRIP-Br3 downregulation. In a further study, the expression levels of TRIP-Br1 and TRIP-Br3 in response to hypoxia were also tested at the transcriptional level and similar result was obtained (Fig. 1C) .
Taken together, our data strongly suggest that hypoxic condition induces TRIP-Br1 upregulation and TRIP-Br3 downregulation at both the transcriptional and protein levels.
Inhibitory role of TRIP-Br1 in hypoxia-induced cell death.
TRIP-Br1 expression significantly increased in the cancer cell lines but not in the normal cell lines under CoCl 2 -generated hypoxic condition. We then sought to determine the cellular function of TRIP-Br1 upregulation. Previously, we showed that TRIP-Br1 functions as an oncoprotein by inhibiting cell death in response to anticancer drug treatment and nutrient/serum starvation (25, 34) . Considering these results, it was presumed that TRIP-Br1 might function in the same way under hypoxic condition. This hypothesis was tested by determining the effect of TRIP-Br1 on cell death.
Among the above cell lines, we chose three major representative cell lines, MCF7, MDA-MB-231, and normal MCF10A for further studies. Since all of the cell lines we used showed very similar results in the expression and functions of TRIPBr1 upon treatment of various stresses including anticancer drug, nutrient depletion, and hypoxia (31,34), we chose three representative cell lines for further studies. These were incubated in growth media with different concentrations of CoCl 2 for 24 h. The phenotypes of cell death in response to hypoxia were photographed under a microscope and the survival rates were measured ( Fig. 2A and B) . Our data showed that the rate of cell death was increased in response to CoCl 2 -induced hypoxia in a dose-dependent manner (Fig. 2B) . Of note, the MCF7 and MDA-MB-231 cancer cells with high levels of TRIP-Br1 protein survived for relatively longer periods of time in response to CoCl 2 treatment, as compared with MCF10A normal cells ( Fig. 2A and B) .
In addition, our data also showed that hypoxia induced apoptosis and autophagy. These results were tested by means of western blot analysis with apoptosis-related regulatory proteins in the CoCl 2 -mediated oxygen-insufficient condition. In Fig. 2C , cleaved PARP and Bax expression levels Gene expression was also assessed with respect to apoptosis and autophagy (i.e., PARP, Bax, and XIAP for apoptosis and SQSTM1/p62 and LC3 for autophagy), with γ-tubulin serving as the loading control. Representative results from three independent experiments are shown.
were increased in the MCF7, MDA-MB-231, and MCF10A cells in proportion to the CoCl 2 concentration. In addition, hypoxia-stimulated autophagy was also examined because this phenomenon is important for achieving cellular homeostasis in response to a variety of stimuli including hypoxia (12, 15, 41, 42) . The level of SQSTM1/p62 expression was decreased in response to CoCl 2 -induced hypoxia in a dose-dependent manner (Fig. 2C) . The conversion ratio from LC3-I to LC3-II was enhanced in response to CoCl 2 -mediated hypoxia (Fig. 2C) . These data obviously suggest that hypoxia can stimulate apoptosis and autophagy, in which TRIP-Br1 expression increased, implying an inhibitory role of TRIP-Br1 in apoptosis and autophagy.
Despite hypoxia being more toxic to cancer cells than to normal cells, many cancer cells are still able to surmount this stressful condition by modulating a cascade of regulatory systems or proteins. We showed that TRIP-Br1 gene expression was significantly increased only in the cancer cells but not in the normal cells under CoCl 2 -evoked hypoxic condition. Our previous report also showed that TRIP-Br1 provides an anti-apoptotic function to cancer cells in response to anticancer drugs and nutrient starvation (25, 34) . Considering these results, it was hypothesized that TRIP-Br1 upregulation might contribute to the enhanced survival of cancer cells under hypoxic condition. This hypothesis is supported by the finding that TRIP-Br1 knock-down in MCF7 and MDA-MB-231 cancer cells accelerated cell death after they were exposed to CoCl 2 (Fig. 2D) . This possibility was also examined using western blot analysis, in which the levels of cleaved PARP and Bax expression increased after TRIP-Br1 silencing in CoCl 2 -containing media and even in complete media (Fig. 2E) . In our previous study, we proposed that TRIP-Br1 could inhibit apoptosis by stabilizing the well-known inhibitor of apoptosis, X-linked inhibitor of apoptosis protein (XIAP) (25) . We also showed that TRIP-Br1 can suppress three types of programed cell deaths (apoptosis, autophagy, and necrosis/necroptosis) via XIAP stabilization (34) . Therefore, XIAP expression levels were measured and found to be greatly decreased after TRIPBr1 silencing in CoCl 2 -containing media, indicating that TRIP-Br1 can inhibit apoptosis by stabilizing XIAP (Fig. 2E) . TRIP-Br1 knock-down also decreased SQSTM1/p62 protein levels and increased the LC3 conversion rate from LC3-I to LC3-II, indicating that TRIP-Br1 represses autophagy as well apoptosis under hypoxic condition (Fig. 2E) .
Taken together, our data suggest that TRIP-Br1 may function as an oncogene by rendering cancer cells resistant to apoptosis through the stabilization of XIAP under stressful hypoxic conditions. 
Effect of PI3K/AKT signaling pathway on TRIP-Br1 expression under CoCl 2 -induced hypoxic condition.
We have shown that hypoxia stimulated much higher levels of TRIP-Br1 expression in cancer cells as compared with normal cells, conferring on cancer cells the ability to develop an enhanced adaptive mechanism for resisting cell death. Our next question was what kind of mechanism is in charge of TRIP-Br1 upregulation in response to hypoxia. It has been widely accepted that oncogenic protein usually stimulates cancer cell proliferation by triggering the activation of a string of signaling pathways, such as the phosphoinositol-3-kinase (PI3K)/AKT signaling pathway. We previously proposed that inhibition of the PI3K/ AKT signaling pathway increased TRIP-Br1 but decreased TRIP-Br3 expression under serum starvation condition (34, 37) . Therefore, we examined the effect of this pathway on TRIPBr1 and TRIP-Br3 expression levels by treating MCF7, MDA-MB-231, and MCF10A cells with LY294002, a PI3K/ AKT inhibitor, in the media along with CoCl 2 . It was found that CoCl 2 -mediated hypoxia inhibited AKT phosphorylation on the 473 serine residue. Of note, inhibition of the PI3K/AKT pathway enhanced TRIP-Br1 upregulation or TRIP-Br3 downregulation under hypoxic condition (Fig. 3) .
These results suggest that hypoxia-induced blockage of the PI3K/AKT signaling pathway is at least partly responsible for the changes in TRIP-Br1 and TRIP-Br3 expression levels in an oxygen-deprived environment. 
HIF-1α-mediated TRIP-Br1 upregulation under hypoxic condition.
It is well known that HIF-1α is a central regulator of the expression of a broad range of genes, including those involved in tumorigenesis (7, 8, 43, 44) . Thus, when we investigated whether or not HIF-1α could affect oncogenic TRIP-Br1 expression, we found that the transfection of HIF-1α-overexpressing plasmid into the MCF7 and MDA-MB-231 cells induced TRIP-Br1 upregulation, as was the case under hypoxic condition at both the protein and the transcriptional levels ( Fig. 4A and B) . Our data also revealed that HIF-1α overexpression induced apoptosis and autophagy in the MCF7 and MDA-MB-231 cancer cells (Fig. 4A) . In contrast, ectopic overexpression of the TRIP-Br1 gene had no effect on HIF-1α expression (Fig. 4C) .
These data suggest that HIF-1α is at least partly responsible for the TRIP-Br1 upregulation under hypoxic condition.
Discussion
Hypoxia has been a major topic in the area of cancer research for many decades. It is commonly found in many cases of solid tumors, in which the tumor cells struggle to adapt to this stressful environment by developing a broad range of cellular mechanisms (7, 8, 12, 15, 18, 44) . In order to identify the mechanism to explain how cancer cells can survive and continue to grow despite being deprived of oxygen, we initially focused on the role of TRIP-Br1 oncoprotein in hypoxia.
Under oxygen-poor conditions, TRIP-Br1 was found to be significantly upregulated in the breast cancer cell lines selected for testing, but was only slightly upregulated in the normal cell lines. This finding underlies the fact that breast cancer cells and normal cells seem to react differently to hypoxia through the regulation of TRIP-Br1 expression. In our study, oxygen deprivation caused injury to cancer and normal cells, inducing apoptosis. However, TRIP-Br1 enables cancer cells to adapt to the stress of hypoxia, thus rending them resistant to cell death. Interestingly, even though TRIP-Br1 and TRIP-Br3 belong to the same TRIP-Br family, their levels of expression changed in opposite change in expression level under hypoxic conditions. These results imply the similar but different cellular functions of TRIP-Br1 and TRIP-Br3. TRIP-Br3 is known to function as a putative tumor suppressor, exerting cellular effects in tumorigenesis that differ from the effects of TRIP-Br1 (37-39). However, our previous study showed that both TRIP-Br1 and TRIP-Br3 can inhibit apoptosis in condition of serum starvation (34,37). As we have now seen in the case of hypoxia, TRIP-Br1 expression levels increased while TRIP-Br3 expression decreased (37) . In normal cells, TRIP-Br3 proteins are rapidly and greatly degraded. Rapid decrease in TRIP-Br3 expression triggers the ubiquitination and degradation of XIAP protein, eventually leading to cell death (37) . In cancer cells, however, TRIP-Br3 expression is slightly downregulated (37) . Therefore, we proposed that TRIP-Br3 and TRIP-Br1 may coordinately regulate apoptosis in normal and cancer cells by competitively interacting with XIAP. Considering our data as a whole, we speculate that TRIP-Br1 and TRIP-Br3 may be under a similar regulatory control system in hypoxic stressful environments. We also suspect that they may act as adopter proteins, functioning differently by changing their binding partners, although this possibility needs to be studied further.
Attention has also been focused on the effect of HIF-1α on TRIP-Br1 expression, because the expression of many genes is known to be regulated by HIF-1α, a key regulator of a wide range of cellular responses to hypoxia in mammalian cells (5, 7, 11, 43) . Our data showed that TRIP-Br1 expression was stimulated by HIF-1α induction in both CoCl 2 -caused hypoxia and exogenous insertion at the transcriptional and translational levels. This finding provides a clue to the notion that HIF-1α may contribute to the TRIP-Br1-mediated resistance of tumor cells to apoptosis caused by hypoxia. Nevertheless, it remains to be determined how HIF-1α promotes TRIP-Br1 upregulation, directly or indirectly, under conditions of oxygen insufficiency.
In summary, our results demonstrate that TRIP-Br1 confers resistance to hypoxia-induced cell death in cancer cells. Thus, targeting TRIP-Br1-mediated cell death under hypoxic condition may provide vital information to those working in cancer research and in the development of effective anticancer drugs.
